Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metvixia fluorescence for vulvar intraepithelial neoplasia
NCT05104099Phase 2Completed
- Sponsor
- Institut de Cancérologie de Lorraine
- Start
- Nov 2021
- Primary completion
- Jun 2024
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methyl aminolevulinate in vulvar intraepithelial neoplasia (VIN), sponsored by Institut de Cancérologie de Lorraine. Primary endpoint: Evaluation of the success of the photodynamic diagnosis at 14 days. Started Nov 2021; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on NCT05104099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104099.